Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Citi
AstraZeneca
Fuji
Deloitte
Express Scripts
Moodys
Covington
Argus Health
Novartis

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,555,877

« Back to Dashboard

Summary for Patent: 8,555,877
Title:Nasal delivery device
Abstract: A delivery device (20, 22) for and a method of delivering a substance to the nasal airway (1) of a subject, in particular the posterior region of the nasal airway, the delivery device comprising: a closure unit for causing the closure of the oropharyngeal velum of the subject; and a delivery unit for delivering a gas flow entraining a substance to one of the nostrils of the subject at such a driving pressure as to flow around the posterior margin of the nasal septum and out of the other nostril of the subject, wherein the delivery unit comprises a nosepiece (30, 40, 58, 82, 102, 132) which includes an outlet through which the gas flow is in use delivered to the one nostril and a sealing member for sealing the one nostril to the outlet such as in use to prevent the escape of the gas flow through the one nostril.
Inventor(s): Djupesland; Per Gisle (Oslo, NO)
Assignee: OptiNose AS (Oslo, NO)
Application Number:11/445,812
Patent Claim Types:
see list of patent claims
Delivery; Device;

Drugs Protected by US Patent 8,555,877

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Avanir Pharms ONZETRA XSAIL sumatriptan succinate POWDER;INHALATION 206099-001 Jan 27, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,555,877

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9904906.6Mar 3, 1999
United Kingdom9911686.5May 19, 1999

Non-Orange Book US Patents Family Members for Patent 8,555,877

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,841,337 Breath-actuated nasal delivery device ➤ Subscribe
8,596,278 Nasal devices ➤ Subscribe
6,715,485 Nasal delivery device ➤ Subscribe
8,511,303 Nasal delivery devices ➤ Subscribe
9,468,727 Nasal delivery ➤ Subscribe
9,205,208 Nasal devices ➤ Subscribe
9,072,857 Nasal delivery device ➤ Subscribe
9,119,932 Nasal delivery device ➤ Subscribe
7,347,201 Nasal delivery devices ➤ Subscribe
7,975,690 Nasal devices ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,555,877

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Turkey 200102563 ➤ Subscribe
Slovenia 1180378 ➤ Subscribe
Slovenia 1161274 ➤ Subscribe
Russian Federation 2337720 ➤ Subscribe
Russian Federation 2003128878 ➤ Subscribe
Russian Federation 2319513 ➤ Subscribe
Russian Federation 2004100276 ➤ Subscribe
Russian Federation 2258538 ➤ Subscribe
Portugal 1180378 ➤ Subscribe
Portugal 1161274 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Baxter
Mallinckrodt
Fish and Richardson
UBS
Federal Trade Commission
McKinsey
Cipla
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot